| Title |
Publication Date |
Price |
Nektar Therapeutics - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Neoprobe Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Medicis Pharmaceutical Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MedCath Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MONOGRAM BIOSCIENCES, INC. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Martek Biosciences Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Neurocrine Biosciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Novartis AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Universal American Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Vasogen Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Triple-S Management Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Southern Cross Healthcare Group PLC - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Perot Systems Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
QLT Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
LifePoint Hospitals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Labopharm Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Grifols, S.A. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Halozyme Therapeutics - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Gilead Sciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Genomic Health, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GPC Biotech AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GenVec, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Illumina, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
InSite Vision Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Inspire Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Javelin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Inovio Biomedical Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Inhibitex, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Incyte Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
deCODE genetics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
eResearchTechnology, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Anadys Pharmaceuticals, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Ardea Biosciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Amicus Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Alnylam Pharmaceuticals, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AmerisourceBergen Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Arena Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Ariad Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioMarin Pharmaceutical Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioSpecifics Technologies Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioCryst Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BELLUS Health Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Auxilium Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Averion International Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Almost Family, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Allos Therapeutics, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ALK-Abello AS - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ARQULE, INC - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AEterna Zentaris Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ADVENTRX Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
etrials Worldwide, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ARYx Therapeutics - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Akorn, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Alexion Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Advanced Life Sciences holdings, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Adolor Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Acorda Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Active Biotech AB - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GENTIUM S.p.A. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Exelixis, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Acura Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Addex Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Actelion Ltd - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Access Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AMDL, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Accelrys, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Adherex Technologies Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Advaxis, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Altus Pharmaceuticals Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Amorfix Life Sciences Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Alseres Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Alizyme plc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Albany Molecular Research, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Alexza Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
3SBio Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
US Oncology, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
HCA, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Highmark Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
E. I. du Pont de Nemours and Company - Strategic Analysis Review
|
June 2009 |
£76 |
Detroit Medical Center - Strategic Analysis Review
|
June 2009 |
£76 |
Apotex, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Carolinas Healthcare system - Strategic Analysis Review
|
June 2009 |
£76 |
Iowa Health System - Strategic Analysis Review
|
June 2009 |
£76 |
Les Laboratoires Servier - Strategic Analysis Review
|
June 2009 |
£76 |
The Cleveland Clinic Foundation - Strategic Analysis Review
|
June 2009 |
£76 |
UPMC - Strategic Analysis Review
|
June 2009 |
£76 |
St. Joseph Health System - Strategic Analysis Review
|
June 2009 |
£76 |
Mission Pharmacal Company - Strategic Analysis Review
|
June 2009 |
£76 |
Lpath, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
MedImmune, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Anesiva, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Ark Therapeutics Group plc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Commonwealth Biotechnologies, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Covance Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Clarient, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
China Sky One Medical, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cerus Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Chembio Diagnostic, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cytori Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Echo Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Eurand N.V. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Exact Sciences Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Epigenomics AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
EpiCept Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Emergent BioSolutions Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
EntreMed, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cepheid - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Caliper Life Sciences Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AutoImmune Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Avigen, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Athersys, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AstraZeneca PLC - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Arpida Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
AspenBio Pharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioDelivery Sciences International, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioSante Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CML Healthcare Income Fund - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CVS Caremark Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CIGNA Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Biodel Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
BioSphere Medical, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Bionovo, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Biovail Corp - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Omnicare, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Owens & Minor, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
OSI Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Noven Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Nissan Chemical Industries, Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Novavax, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
PDL BioPharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Pain Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Santarus, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Rigel Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Res-Care, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Par Pharmaceutical Companies, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Quest Diagnostics Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Neurogen Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Nabi Biopharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Manhattan Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Maxygen, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Magellan Health Services, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MDRNA, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Lotus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MAP Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MediciNova, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Medivation, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Mymetics Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
NPS Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Mylan Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Molecular Insight Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Metabasis Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
MethylGene Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Savient Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Sunesis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cadence Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GlaxoSmithKline plc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CHRISTUS Health - Strategic Analysis Review
|
June 2009 |
£76 |
Arrow International, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Micromet, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Sanofi-Aventis - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ISTA Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Ipsen S.A. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Standard Life plc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Vital Signs, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Novo Nordisk A/S - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Millipore Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Keryx Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
LifeCycle Pharma A/S - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Intuitive Surgical, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Bayer AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Vertex Pharmaceuticals Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ViroPharma Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
VIVUS, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
UnitedHealth Group Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
SuperGen, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Tenet Healthcare Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Warner Chilcott Limited - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Waters Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Amgen Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Antares Pharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ZymoGenetics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
WellPoint, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Watson Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Lexicon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
La Jolla Pharmaceutical Company - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cytokinetics, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
DUSA Pharmaceuticals, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cypress Bioscience, Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Curis, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cubist Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CuraGen Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Depomed, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Discovery Laboratories, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Express Scripts, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Flamel Technologies S.A. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Elan Corporation, plc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Dyax Corp. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
EPIX Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Crucell N.V. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cougar Biotechnology, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Celesio AG - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Celgene Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cardiome Pharma Corp - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Callisto Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Boiron SA - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CV Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cell Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Celldex Therapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
CombinatoRx, Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cortex Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Columbia Laboratories Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Chelsea Therapeutics International, Ltd. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Cephalon, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Chattem, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GTC Biotherapeutics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GTx, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Idenix Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
IR Biosciences Holdings, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
IMS Health Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
ICAgen Inc - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
IDM Pharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Insmed Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
InterMune, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
King Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
LCA-Vision Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Kindred Healthcare, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Karo Bio - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Isis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Jazz Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Human Genome Sciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Hikma Pharmaceuticals - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Genta Incorporated - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
GeoVax Labs, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Genmab AS - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Genentech, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Gedeon Richter Plc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Genaera Corporation - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
H Lundbeck AS - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Hana Biosciences, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Hemispherx Biopharma, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Heska Corp - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Helix BioMedix, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Health Net, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Health Management Associates, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
APP Pharmaceuticals, Inc. - Strategic Analysis Review
|
June 2009 |
£76 |
Antigenics, Inc. - Financial and Strategic Analysis Review
|
June 2009 |
£76 |
Private healthcare market in Poland 2009
Development forecast for 2009-2011 Plus: Non-public hospitals in Poland database
|
May 2009 |
£1460 |
Good Clinical Practice
A Question & Answer Reference Guide 2009
|
May 2009 |
£30 |
Antisense Therapeutics Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Apria Healthcare Group Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Arana Therapeutics Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Asahi Kasei Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
AtheroGenics, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Astellas Pharma Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Amarin Corporation plc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Yakult Honsha Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Agenix ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
AXM Pharma, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
AVANIR Pharmaceuticals - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Accentia Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
International Travel and Health 2009
|
April 2009 |
£15 |
Auriga Laboratories Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Advanced Proteome Therapeutics Corp. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Allergy Therapeutics plc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Avita Medical Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Winn-Dixie Stores, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Wipro Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Cerebos Pacific Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Cobalis Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Corgenix Medical Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Community Health Systems, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Cadence Pharmaceuticals - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
CSL Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
BTG International Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Wyeth - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Barr Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Bayer Schering Pharma AG - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Bioxel Pharma Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Biota Holdings Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Avalon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
STADA Arzneimittel AG - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Generex Biotechnology Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Genelabs Technologies, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
GammaCan International Inc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Genetic Technologies Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
GeoPharma, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Immucor, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Henry Schein, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Favrille, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Evotec Aktiengesellschaft - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Clinical Data, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Chugai Pharmaceutical Co. Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Derma Sciences, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Emageon Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Endovasc, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Endocare, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Indevus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Introgen Therapeutics, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
OXIS International, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
North American Scientific, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
PerkinElmer, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Rite Aid Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Coventry Health Care, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Rockwell Medical Technologies, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Nanogen, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Minrad International, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
KYOWA HAKKO KOGYO Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Inyx, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Laboratory Corporation of America Holdings - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Mediware Information Systems, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Meridian Bioscience, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Mentor Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Teijin Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Takeda Pharmaceutical Company Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Tercica, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Teva Pharmaceutical Industries Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Myriad Genetics, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Takara Holdings Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
NeoPharm, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Solvay SA - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Mitsubishi Tanabe Pharma Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
MicroIslet Inc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
MacroChem Corp. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Lorus Therapeutics Inc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Matrixx Initiatives, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Med Gen Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Meldex International PLC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Meiji Seika Kaisha, Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Neose Technologies, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Shire Plc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Pfizer Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
PSS World Medical, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Progenics Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Protherics PLC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
SYSCO Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Publix Super Markets, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Oramed Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Onyx Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Sciele Pharma, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Nippon Kayaku Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Schwarz Pharma AG - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
OPG Groep - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Ono Pharmaceutical Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Schering-Plough Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Lonza Group Ltd - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Lipid Sciences, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
HEALTHWAYS, INC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
GW Pharmaceuticals plc - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Virbac Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Humana Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
IMUGENE LIMITED - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
IMAGENETIX, INC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Forest Laboratories, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Enzon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Dainippon Sumitomo Pharma Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Ceapro Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Denki Kagaku Kogyo Kabushiki Kaisha - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
E.I. du Pont de Nemours and Company - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Eisai Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
ENZO BIOCHEM, INC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Unitika LTD. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Iasis Healthcare LLC - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Kuraray Co., Ltd. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
UCB Group - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
General Practice Medical Services in Australia
IBISWorld Industry Report
|
April 2009 |
£360 |
Lannett Company, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
LifeCycle Pharma AS - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Lescarden Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Keryx Biopharmaceuticals - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Kendle International Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Immtech Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
ImClone Systems Incorporated - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
ImmunoGen, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Immunomedics, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Japan Tobacco Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Nursing Homes in Australia
IBISWorld Industry Report
|
April 2009 |
£360 |
Cyanotech Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Ramsay Health Care Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Akzo Nobel N.V. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Alchemia Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
A Practical Guide to Licensing Herbal Medicinal Products
First Edition
|
April 2009 |
£250 |
Emergency & Other Outpatient Care Centers in the US
IBISWorld Industry Report
|
April 2009 |
£395 |
Biomerica, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Akesis Pharmaceuticals Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Home Care Providers in the US
IBISWorld Industry Report
|
April 2009 |
£395 |
Alfacell Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Alkermes, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Alliance Pharmaceutical Corp. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Specialist Doctors in the US
IBISWorld Industry Report
|
April 2009 |
£395 |
Avexa Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Agilent Technologies Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Avitar, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Healthcare Communication
First Edition
|
April 2009 |
£29.95 |
BioTime, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Aeolus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Agfa-Gevaert N.V. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Bioniche Life Sciences - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Advanced Viral Research Corp. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Foodborne Disease Outbreaks. Guidelines for Investigation and Control
|
April 2009 |
£15 |
Advanced Cell Technology, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Acusphere, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
CEL-SCI Corporation - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Substance Abuse & Mental Health Facilities in the US
IBISWorld Industry Report
|
April 2009 |
£395 |
Air Products and Chemicals, Inc. - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Biotron Limited - Financial and Strategic Analysis Review
|
April 2009 |
£76 |
Industry Guide to Good Hygiene Practice: Retail
|
April 2009 |
£10 |
General Hospitals in Australia
IBISWorld Industry Report
|
April 2009 |
£360 |
Private healthcare market in Central and Eastern Europe 2009
|
March 2009 |
£2145 |
Quintiles Transnational Corp. - Strategic Analysis Review
|
March 2009 |
£76 |
Radiation Therapy Services, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Ratiopharm direct GmbH - Strategic Analysis Review
|
March 2009 |
£76 |
Provena Health - Strategic Analysis Review
|
March 2009 |
£76 |
NewYork- Presbyterian Hospital - Strategic Analysis Review
|
March 2009 |
£76 |
Resurrection Health Care - Strategic Analysis Review
|
March 2009 |
£76 |
Partners HealthCare System, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Premera Blue Cross - Strategic Analysis Review
|
March 2009 |
£76 |
Providence Health System - Strategic Analysis Review
|
March 2009 |
£76 |
Purdue Pharma L.P. - Strategic Analysis Review
|
March 2009 |
£76 |
Vanguard Health Systems, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
The Regence Group - Strategic Analysis Review
|
March 2009 |
£76 |
Trinity Health - Strategic Analysis Review
|
March 2009 |
£76 |
New York City Health and Hospitals Corporation - Strategic Analysis Review
|
March 2009 |
£76 |
Wellmont Health System - Strategic Analysis Review
|
March 2009 |
£76 |
Sutter Health - Strategic Analysis Review
|
March 2009 |
£76 |
Spectrum Health System - Strategic Analysis Review
|
March 2009 |
£76 |
SSM Health Care System Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Scripps Health - Strategic Analysis Review
|
March 2009 |
£76 |
Sisters of Mercy Health System - Strategic Analysis Review
|
March 2009 |
£76 |
Roche Holding Ltd - Strategic Analysis Review
|
March 2009 |
£76 |
Kinray, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Beverly Enterprises - Strategic Analysis Review
|
March 2009 |
£76 |
Baylor Health Care System - Strategic Analysis Review
|
March 2009 |
£76 |
Barrier Therapeutics, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Biotech Holdings Ltd. - Strategic Analysis Review
|
March 2009 |
£76 |
Blue Cross Blue Shield of Michigan - Strategic Analysis Review
|
March 2009 |
£76 |
Accommodation for the Aged in Australia
IBISWorld Industry Report
|
March 2009 |
£360 |
Catholic Health Initiatives - Strategic Analysis Review
|
March 2009 |
£76 |
Blue Cross and Blue Shield of Massachusetts, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Axcan Pharma Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Ardent Health Services LLC - Strategic Analysis Review
|
March 2009 |
£76 |
Asia-Pacific Enterprise Communications in the Hospitality
|
March 2009 |
£7320 |
Pediatric Health Care Products and Services
|
March 2009 |
£2960 |
Retail Clinics and The in-Store Healthcare Market 2009
Bright Spot in The Current Economy?
|
March 2009 |
£2135 |
AAIPharma Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Accredo Health Group, Inc - Strategic Analysis Review
|
March 2009 |
£76 |
AlphaRx, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Alliance Boots GmbH - Strategic Analysis Review
|
March 2009 |
£76 |
Actavis Group hf. - Strategic Analysis Review
|
March 2009 |
£76 |
Catholic Health Services of Long Island - Strategic Analysis Review
|
March 2009 |
£76 |
Chr. Hansen Holding AS - Strategic Analysis Review
|
March 2009 |
£76 |
Lee Memorial Health System - Strategic Analysis Review
|
March 2009 |
£76 |
Nursing Care Facilities in the US
IBISWorld Industry Report
|
March 2009 |
£395 |
Katz Group Canada Ltd. - Strategic Analysis Review
|
March 2009 |
£76 |
Life Care Centers of America - Strategic Analysis Review
|
March 2009 |
£76 |
MGI Pharma Inc - Strategic Analysis Review
|
March 2009 |
£76 |
Merck Serono S.A. - Strategic Analysis Review
|
March 2009 |
£76 |
Pathology Services in Australia
IBISWorld Industry Report
|
March 2009 |
£345 |
MedStar Health - Strategic Analysis Review
|
March 2009 |
£76 |
Intermountain Healthcare, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Inova Health System - Strategic Analysis Review
|
March 2009 |
£76 |
Dental Services in Australia
IBISWorld Industry Report
|
March 2009 |
£345 |
DSM N.V. - Strategic Analysis Review
|
March 2009 |
£76 |
Ambulance Services in the US
IBISWorld Industry Report
|
March 2009 |
£395 |
EGIS Pharmaceuticals Plc - Strategic Analysis Review
|
March 2009 |
£76 |
Group Health Cooperative - Strategic Analysis Review
|
March 2009 |
£76 |
InNexus Biotechnology Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
ISTA Pharmaceuticals, Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Mountain States Health Alliance - Strategic Analysis Review
|
March 2009 |
£76 |
Texas Health Resources Inc. - Strategic Analysis Review
|
March 2009 |
£76 |
Dentists in the US
IBISWorld Industry Report
|
March 2009 |
£395 |
Specialty Hospitals in the US
IBISWorld Industry Report
|
March 2009 |
£395 |
Psychiatric Hospitals in Australia
IBISWorld Industry Report
|
February 2009 |
£345 |
Community Health Centres in Australia
IBISWorld Industry Report
|
February 2009 |
£345 |
Podiatrists & Other Health Care Practitioners in the US
IBISWorld Industry Report
|
February 2009 |
£395 |
Chiropractors in the US
IBISWorld Industry Report
|
February 2009 |
£395 |
Negotiating The Emerging Biosimilars Landscape
Key Developments in The Regulatory Environment
|
February 2009 |
£2025 |
Optometry and Optical Dispensing in Australia
IBISWorld Industry Report
|
February 2009 |
£345 |
Technology Transfer Strategies: Maximizing the returns from new technologies
|
February 2009 |
£2025 |
Diagnostic Imaging Services in Australia
IBISWorld Industry Report
|
February 2009 |
£345 |
Anthrax in Humans and Animals
|
February 2009 |
£24 |
Retirement Communities in the US
IBISWorld Industry Report
|
January 2009 |
£395 |
The 100 Biggest Acute Hospitals In Europe
|
January 2009 |
£595 |
The Epigenetics Healthcare R&D, Products and Commercial Implications
Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook
|
January 2009 |
£1025 |
Optometrists in the US
IBISWorld Industry Report
|
December 2008 |
£395 |
Medical Supplies Wholesaling in the US
IBISWorld Industry Report
|
December 2008 |
£395 |
Global Medical Tourism
|
December 2008 |
£2075 |
European Hospital Register, The
|
Ongoing |
£1500 |
Chiropractic Services in Australia
IBISWorld Industry Report
|
November 2008 |
£435 |
Why Do Drugs Fail?
|
November 2008 |
£995 |
Physiotherapy Services in Australia
IBISWorld Industry Report
|
November 2008 |
£435 |
Clinical Laboratory Services Market
(Growth Opportunities, Competitive Analysis and Competitor Profiles)
|
November 2008 |
£1525 |
MarketWatch: Health Roundup
|
November 2008 |
£215 |
Stakeholder Insight: Osteoporosis
Generic alendronate further establishes oral bisphosphonates as gold standard
|
October 2008 |
£8000 |
MarketWatch: Health Round-up
|
October 2008 |
£215 |
North American Fetal and Neonatal Patient Monitoring Markets
|
October 2008 |
£2970 |
RNA therapy: the next big thing after monoclonal antibodies?
|
October 2008 |
£4000 |
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth
|
October 2008 |
£8000 |
Access to Hospital Pharmaceutical Markets in the United Kingdom
|
September 2008 |
£850 |
Western Europe, Healthcare Sector Pulse, April-June 2008
|
September 2008 |
£880 |
Sales Force Effectiveness
|
September 2008 |
£4000 |
World Healthcare Security Market
|
September 2008 |
£3960 |
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
|
September 2008 |
£8000 |
British National Formulary
|
September 2008 |
£27.95 |
Financial Deals Industry Tracker
Pharmaceuticals and Healthcare August 2008 (Analysis of Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
|
September 2008 |
£265 |
Medical Tourism Facts and Figures 2008
|
September 2008 |
£600 |
Cardiovascular Biomarkers: Players, products and prospects (Volume III)
|
August 2008 |
£595 |
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
|
August 2008 |
£1495 |
CNS Biomarkers: Players, products and prospects (Volume II)
|
August 2008 |
£595 |
Cancer Biomarkers: Players, products and prospects (Volume I)
|
August 2008 |
£595 |
Telemedicine Gets a Big Boost from the Feds
|
August 2008 |
£2745 |
Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking
|
August 2008 |
£7600 |
Forecast Insight: Antidiabetics - Switching to new molecule antidiabetics drives market growth
|
August 2008 |
£7600 |
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus
Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts
|
August 2008 |
£7600 |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
|
August 2008 |
£3800 |
Commercial Insight: Antihormonal Therapy Cancer Brands
Careful Lifecycle Management Needed to Preserve Brand Dominance
|
August 2008 |
£7600 |
Commercial Insight: HIV - The battle for market share is getting fiercer
|
August 2008 |
£7600 |
Forecast Insight: Multiple Sclerosis
Tysabri to prevail despite safety setbacks
|
August 2008 |
£7600 |
Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market
|
August 2008 |
£7600 |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare July 2008
(Analysis of Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
|
August 2008 |
£265 |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
August 2008 |
£670 |
Health Care Equipment & Supplies in Canada
|
July 2008 |
£180 |
Health Care Equipment & Supplies in the United Kingdom
|
July 2008 |
£180 |
Health Care Equipment & Supplies in the United States
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Europe
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Belgium
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Asia-Pacific
|
July 2008 |
£180 |
Global Health Care Equipment & Supplies
|
July 2008 |
£180 |
Health Care Equipment & Supplies in China
|
July 2008 |
£180 |
Health Care Equipment & Supplies in France
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Japan
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Italy
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Germany
|
July 2008 |
£180 |
Health Care Equipment & Supplies in the Netherlands
|
July 2008 |
£180 |
Health Care Equipment & Supplies in Spain
|
July 2008 |
£180 |
Commercial Insight: Targeted Therapy Cancer Brands
High Growth Market Will See Eight New Blockbusters by 2017
|
July 2008 |
£7600 |
Commercial Insight: Cytotoxic Therapy Cancer Brands
Looming Patent Expiries Limit Market Growth
|
July 2008 |
£7600 |
Bristol-Myers Squibb Co.: PharmaVitae Profile
|
July 2008 |
£3010 |
Novo Nordisk A/S: PharmaVitae Profile
|
July 2008 |
£3010 |
Generic Series: Optimizing Brand Lifecycle Management
Winning Strategies to Maximize Revenue in The Face of Growing Generic Competition
|
July 2008 |
£3800 |
Pipeline Insight: Insulin Antidiabetics
Return to Injections Alternative Delivery Methods Fall by The Wayside
|
July 2008 |
£6000 |
Argentina Pharmaceuticals and Healthcare Report Q3 2008
|
July 2008 |
£425 |
Stakeholder Opinions: Diagnostics in Neurology
Predictive Biomarkers Expand Drug Revenues
|
July 2008 |
£2005 |
Bon Secours Health System, Inc. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Upmc Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Group Health Incorporated Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Allina Hospitals and Clinics Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Ssm Health Care System Inc. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Premera Blue Cross Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Banner Health Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Radiation Therapy Services, Inc. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Adventist Health System Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Horizon Healthcare Services, Inc. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Universal American Corp. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
MedStar Health Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
The Regence Group Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
The Cleveland Clinic Foundation Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Partners HealthCare System, Inc. Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Triple-S Management Corporation Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Provena Health Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Mountain States Health Alliance Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Detroit Medical Center Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
|
July 2008 |
£7700 |
Iowa Health System Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Resurrection Health Care Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
Cvs Caremark Corporation Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Scripps Health Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Cigna Corporation Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Carolinas Healthcare System Healthcare
Managed Care & Hospitals SWOT Report
|
July 2008 |
£76 |
Long-Term Care Market
Nursing Homes, Home Care, Hospice Care, and Assisted Living
|
July 2008 |
£1230 |
Stakeholder Insight
Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma
|
July 2008 |
£7600 |
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare
(Analysis of Monthly Deal Activity, along with The Trend for The Last Six Months for Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
|
June 2008 |
£265 |
Asian Medical Tourism Analysis
2008-2012
|
June 2008 |
£430 |
Allergan, Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Advanced Ocular Systems Limited Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Aethlon Medical, Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
ADM Tronics Unlimited, Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Unomedical Holding as Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Acrux Limited Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Adaltis Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Vivolution A/S Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Accellent Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Abcam plc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£76 |
Global Health Care Supplies
|
May 2008 |
£230 |
China Membrane Market Report
2007-2008
|
April 2008 |
£615 |
Emerging Medical Tourism
Thailand 2008
|
April 2008 |
£800 |
The Pharmaceutical Industry 2008
Current and Future Trends and Strategic Issues Shaping Pharma
|
March 2008 |
£3010 |
Impact of Pharmacogenomics on Public Healthcare Policy
Educating Patients, Payors and Healthcare Providers
|
March 2008 |
£1995 |
Private healthcare market in Poland 2008
Development forecasts for
> 2008-2010
|
March 2008 |
£950 |
Non Voice BPO in Healthcare
|
March 2008 |
£600 |
Health 2.0 and Telecare for The Elderly
|
January 2008 |
£195 |
Surgical Robot Market Shares, Market Strategies, and Market Forecasts, 2008-2014
|
January 2008 |
£2015 |
Medical Tourism 2008
The World-wide Business Guide
|
December 2007 |
£1500 |
Premium Company Profile: DURECT Corporation
|
November 2007 |
£265 |
Growing 'Out of Pocket' Healthcare Market
Spending on Surgeries, Pharmaceuticals and Other Healthcare Services
|
November 2007 |
£1000 |
Growing 'Out of Pocket' Healthcare Market
Spending on Surgeries, Pharmaceuticals and Other Healthcare Services
|
November 2007 |
£2225 |
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure changes for the better
Healthcare
|
October 2007 |
£7600 |
Commercial Insight: Cardiovascular market overview
Raft of patent expires threaten blockbusters
|
October 2007 |
£7600 |
Commercial Insight: Antithrombotics
Market expands as disease management focuses on prevention
|
October 2007 |
£7600 |
Healthcare Opportunities for Food Ingredient Manufacturers
|
October 2007 |
£1825 |
Indian System of Medicine Industry Report
|
October 2007 |
£400 |
Snapshots UK Private Healthcare Services 2007
|
September 2007 |
£150 |
Healthcare Technology Telehealth's Increasing Role In Healthcare (Review Report)
|
September 2007 |
£1795 |
Indian Health Insurance
|
September 2007 |
£600 |
Retail Clinics, The Emerging Market for Convenience and In-Store Healthcare
|
September 2007 |
£1825 |
The Current Status and Development Direction of Chinese Hospitals
|
August 2007 |
£120 |
Health Care Equipment & Supplies
Global Industry Guid
|
August 2007 |
£525 |
Future of Biosimilars, The
Key opportunities & emerging therapies
|
August 2007 |
£1495 |
Specialist Medical Services in Australia
IBISWorld Industry Report
|
July 2007 |
£430 |
Ambulance Services in Australia
IBISWorld Industry Report
|
July 2007 |
£405 |
Home Health Care Services in the US
IBISWorld Industry Report
|
July 2007 |
£395 |
Other Outpatient Care Centers in the US
IBISWorld Industry Report
|
July 2007 |
£395 |
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
|
July 2007 |
£7600 |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
Patient Empowerment
Empowered Patients Can Change Healthcare Outcomes And Impact The Pharmaceutical Industry
|
July 2007 |
£3000 |
Hospitals (Except Psychiatric Hospitals) in Australia
IBISWorld Industry Report
|
June 2007 |
£430 |
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
|
June 2007 |
£7600 |
China Medicated Health Product Industry Report
2007
|
June 2007 |
£275 |
Telehealth Spending in North America and Europe Through 2012
Interactive Model
|
June 2007 |
£7915 |
The Global Anti-Infectives Market Outlook to 2011
|
June 2007 |
£1495 |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
Snapshots UK Healthcare Services 2007
|
May 2007 |
£150 |
Chinese Medical Insurance System in a Dilemma
|
May 2007 |
£92 |
General Hospitals in China
IBISWorld Industry Report
|
May 2007 |
£380 |
U.S. Market for Home Care Products, 5th Edition
|
May 2007 |
£2435 |
Family Planning Centers in the US
IBISWorld Industry Report
|
April 2007 |
£395 |
Psychiatric and Substance Abuse Hospitals in the US
IBISWorld Industry Report
|
April 2007 |
£395 |
Other Residential Care Facilities in the US
IBISWorld Industry Report
|
April 2007 |
£395 |
China Blood Product Industry Report, 2006-2007
|
April 2007 |
£245 |
Business Trends Healthcare Technology
Understanding your Healthcare Customer (Customer Focus)
|
March 2007 |
£1795 |
Residential Mental Health and Substance Abuse Facilities in the US
IBISWorld Industry Report
|
March 2007 |
£395 |
Enabling Translational Medicine with BI (Technology Focus)
|
March 2007 |
£1000 |
General Medical and Surgical Hospitals in the US
IBISWorld Industry Report
|
March 2007 |
£395 |
2007 Trends to Watch: Pharmaceutical Technology
|
March 2007 |
£947.5 |
2007 Trends to Watch: Healthcare Technology
|
February 2007 |
£947.5 |
Remaining Competitive in Digital Imaging (Strategy Focus)
|
February 2007 |
£947.5 |
Reducing Medical Error and Improving Diagnostics through Digital Imaging (Review Report)
|
February 2007 |
£1795 |
Community Care Facilities for the Elderly in the US
IBISWorld Industry Report
|
February 2007 |
£395 |
All Other Ambulatory Health Care Services in the US
IBISWorld Industry Report
|
February 2007 |
£395 |
Health and Wellness Healthcare Products in Spain
|
February 2007 |
£650 |
Patient Education and Direct-to-Patient Communication
|
February 2007 |
£2680 |
Addressing the Challenges of Consumer-driven Healthcare (Review Report)
|
January 2007 |
£1795 |
Healthcare Technology Quarterly Briefing Q4 2006
|
January 2007 |
£1000 |
Residential Care Services n.e.c. in Australia
IBISWorld Industry Report
|
January 2007 |
£415 |
Non-Residential Care Services n.e.c. in Australia
IBISWorld Industry Report
|
January 2007 |
£460 |
2007 Worldwide Nursing Care Facilities Industry Report
|
January 2007 |
£120 |
2007 Worldwide Medical & Surgical Hospitals Industry Report
|
January 2007 |
£120 |
2007 Worldwide Health & Medical Insurance Carriers Industry Report
|
January 2007 |
£120 |
2007 Worldwide Home Health Care Services Industry Report
|
January 2007 |
£120 |
Indian Healthcare Services Industry Report
|
January 2007 |
£400 |
Health and Wellness Healthcare Products in Mexico
|
January 2007 |
£650 |
Health and Wellness Healthcare Products in Netherlands
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Russia
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Finland
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Sweden
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Brazil
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Denmark
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Norway
|
December 2006 |
£650 |
Health and Wellness Healthcare Products in Ireland
|
December 2006 |
£650 |
Opportunities in Medical Tourism in India (2007)
|
December 2006 |
£240 |
International and Expatriate Health Insurance
|
December 2006 |
£1500 |
Health and Wellness Healthcare Products in Switzerland
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Australia
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Canada
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Hong Kong, China
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in India
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Indonesia
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Austria
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Belgium
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in South Korea
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in Germany
|
November 2006 |
£650 |
Health and Wellness Healthcare Products in China
|
November 2006 |
£650 |
Helping Healthcare Organizations Compete in a Consumer-driven Environment (Customer Focus)
|
November 2006 |
£1000 |
Chinese Markets for Health Care
|
November 2006 |
£2440 |
2007 U.S. Home Health Care Services Industry Report
|
October 2006 |
£91 |
2007 U.S. Health & Medical Insurance Carriers Industry Report
|
October 2006 |
£91 |
2007 U.S. Medical & Surgical Hospitals Industry Report
|
October 2006 |
£91 |
2007 U.S. Nursing Care Facilities Industry Report
|
October 2006 |
£91 |
Health Services n.e.c. in Australia
IBISWorld Industry Report
|
September 2006 |
£405 |
Patients as Consumers
Understanding the Increasing Consumer Level of Influence in Healthcare
|
August 2006 |
£2195 |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£1200 |
Women's Health
Worldwide Prescription Drug Markets
|
August 2006 |
£2380 |
Mobility Aids & Accessories Worldwide
A Market Strategy Report
|
June 2006 |
£1215 |
Role of the Private Sector in the European Healthcare Market, The
|
June 2006 |
£2500 |
Snapshots US Nursing Home Care 2006
|
May 2006 |
£150 |
Snapshots US Healthcare Services 2006
|
May 2006 |
£150 |
Snapshots US Hospitals 2006
|
May 2006 |
£150 |
Snapshots US Home Healthcare 2006
|
May 2006 |
£150 |
Health and Wellness Healthcare Products in France
|
May 2006 |
£650 |
Hospital Supply Chain Management
Sector Snapshot
|
May 2006 |
£305 |
European Hospital Purchasing Practices
Sector Snapshot
|
April 2006 |
£305 |
Robotics and Orthopedic Surgery
Sector Snapshot
|
April 2006 |
£305 |
Outpatient Mental Health and Substance Abuse Centers in the US
IBISWorld Industry Report
|
April 2006 |
£395 |
Specialty (except Psychiatric and Substance Abuse) Hospitals in the US
IBISWorld Industry Report
|
April 2006 |
£395 |
Offices of Mental Health Practitioners (except Physicians) in the US
IBISWorld Industry Report
|
April 2006 |
£395 |
Health and Wellness Healthcare Products in Hong Kong
|
April 2006 |
£650 |
The Changing Patient-Physician Relationship Part 2
The Physician's Perspective
|
January 2006 |
£2195 |
Residential Mental Retardation Facilities in the US
IBISWorld Industry Report
|
January 2006 |
£395 |
The Changing Patient-Physician Relationship Part 1
The Patient's Perspective
|
January 2006 |
£2195 |
Health and Wellness Healthcare Products in Thailand
|
January 2006 |
£650 |
Health and Wellness Healthcare Products in Greece
|
January 2006 |
£650 |
Health and Wellness Healthcare Products in Japan
|
January 2006 |
£650 |
Health and Wellness Healthcare Products in the UK
|
January 2006 |
£650 |
Health and Wellness Healthcare Products in Italy
|
January 2006 |
£650 |
Health and Wellness Healthcare Products in the Netherlands
|
December 2005 |
£650 |
Reissuing pharmaceuticals in the NHS
Challenging the chain of trust
|
October 2005 |
£600 |
Snapshots US Healthcare Services 2005
|
April 2005 |
£150 |
Snapshots US Hospitals 2005
|
April 2005 |
£150 |
Snapshots US Nursing Home Care 2005
|
April 2005 |
£150 |
Snapshots US Home Healthcare 2005
|
April 2005 |
£150 |
Snapshots UK Healthcare Services 2005
|
April 2005 |
£150 |
Essentials of Economic Evaluation in Healthcare
|
January 2005 |
£25.95 |
An Assessment of Current Healthcare IT Application Profiles
and the Future Outlook in Europe
|
January 2005 |
£1335 |
Continuous Improvement in the Healthcare Manufacturing Industry
A Practical Guide
|
September 2003 |
£110 |
Healthcare in a Recession
(OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics)
|
March 2003 |
£1215 |
Handbook of Pharmacy Healthcare
Diseases and patient advice, 2nd Edition
|
August 2002 |
£39.95 |
UK Private Healthcare Market Development Report
|
July 2001 |
£600 |
UK Domiciliary Healthcare Market Development Report
|
July 2001 |
£600 |
UK Dentistry Market Development Report
|
June 2001 |
£600 |
UK Complimentary & Alternative Medicines Market Development Report
|
June 2001 |
£600 |
UK Vitamins & Mineral Supplements
|
May 2001 |
£600 |
UK Public Expenditure on Health
|
May 2001 |
£600 |
UK Health & Fitness Clubs Market Development Report
|
April 2001 |
£600 |
UK Residential Care for the Elderly Market Development Report
|
April 2001 |
£600 |
